UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010805
Receipt number R000012647
Scientific Title A Phase II study of Pemetrexed/Bevacizumab in patients ineligible for platinum-based chemotherapy with untreated Advanced Non-squamous non-small-cell lung cancer (ALCT003)
Date of disclosure of the study information 2013/05/26
Last modified on 2015/06/07 01:10:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Phase II study of Pemetrexed/Bevacizumab in patients ineligible for platinum-based chemotherapy with untreated Advanced Non-squamous non-small-cell lung cancer (ALCT003)

Acronym

A Phase II study of PEM/Bev in patients ineligible for platinum-based chemotherapy with untreated Advanced Non-sq NSCLC (ALCT003)

Scientific Title

A Phase II study of Pemetrexed/Bevacizumab in patients ineligible for platinum-based chemotherapy with untreated Advanced Non-squamous non-small-cell lung cancer (ALCT003)

Scientific Title:Acronym

A Phase II study of PEM/Bev in patients ineligible for platinum-based chemotherapy with untreated Advanced Non-sq NSCLC (ALCT003)

Region

Japan


Condition

Condition

Non-squamous Non-small cell lung cancer

Classification by specialty

Pneumology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

This study evaluated the efficacy and safety of pemetrexed plus bevacizumab as front-line treatment of advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

progression free surviaval

Key secondary outcomes

Response rate, Overall survival, QOL,Time to response,Safety,evaluation of thymidylate synthase protein expression


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Pemetrexed plus Bevacizumab as front-line treatment

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) histologically or cytologically
confirmed
2)newly diagnosed stage IIIB,IV
3)recurrent NSCLC for which they had not received chemotherapy
4)measurable or nonmeasurable disease as
defined by Response Evaluation Criteria in Solid Tumors
5)age 20-69 Performance status:2
age 70-74 Performance status:1-2
age 75&#8804; Performance status:0-2
Patients ineligible for platinum-based
chemotherapy
6)adequate hematologic, hepatic, and renal functions
7)Patients expected to survive longer than at least three months
8)patients with a history of brain metastases after treatments more than a week ago
9)Patients who provide written informed consent

Key exclusion criteria

1)active double cancer
2)clinically significant infectious disease
3)history of gross hemoptysis (2.5ml) 4)regular use of aspirin
5)history of diverticulitis or clinically significant diverticular disease
6)clinically significant cardiovascular disease and DVT
7)medically uncontrolled hypertension and diabetes
8)active or symptomatic interstitial lung disease
9)Patients with the plan of operation or thoracic irradiation
10)Patients with wound that has not quite healed
11)pregnancy or lactation

Target sample size

25


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takuma Yokoyama

Organization

Kyorin Univercity Hospital

Division name

Department of Respiratory Medicine

Zip code


Address

6-20-2 shinkawa, Mitaka city,Tokyo

TEL

0422-47-5511

Email

taku@ks.kyorin-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takuma Yokoyama

Organization

Kyorin Univercity Hospital

Division name

Department of Respiratory Medicine

Zip code


Address

6-20-2 shinkawa, Mitaka city,Tokyo

TEL

0422-47-5511

Homepage URL


Email

taku@ks.kyorin-u.ac.jp


Sponsor or person

Institute

Department of Respiratory Medicine Kyorin Univercity Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 05 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2012 Year 11 Month 22 Day

Date of IRB


Anticipated trial start date

2013 Year 04 Month 25 Day

Last follow-up date

2015 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 05 Month 26 Day

Last modified on

2015 Year 06 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012647


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name